Last reviewed · How we verify
Fortaz (Ceftazidime)
Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance.
Ceftazidime is a third-generation cephalosporin indicated for serious infections caused by susceptible Gram-negative and Gram-positive organisms including Pseudomonas aeruginosa. The drug demonstrates bactericidal activity through cell wall inhibition with favorable pharmacokinetics including short half-life and minimal protein binding. Primary risks include hypersensitivity reactions and potential nephrotoxicity when combined with aminoglycosides or diuretics. Ceftazidime remains an important empiric therapy option for severe infections in hospitalized and immunocompromised patients.
At a glance
| Generic name | Ceftazidime |
|---|---|
| Sponsor | Pai Holdings Pharm |
| Drug class | Third-generation cephalosporin |
| Target | Bacterial cell wall |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1985 |
Mechanism of action
Ceftazidime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. The drug has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria, providing broader spectrum coverage than earlier generation cephalosporins.
Approved indications
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial meningitis
- Bacterial pneumonia
- Bacterial septicemia
- Bacterial urinary infection
- Citrobacter Pneumonia
- Complicated Proteus UTI
- Complicated UTI with Pseudomonas Aeruginosa
- E. Coli Cervicitis
- E. Coli Endometritis
- E. Coli Gynecological Infections
- E. Coli Pelvic Cellulitis
- E. Coli Pelvic Inflammatory Disease
- E. Coli Peritonitis
- Ecthyma gangrenosum
- Endometritis
- Enterobacter Osteomyelitis
- Enterobacter Pneumonia
- EnterobacterJoint Infection
- Escherichia coli urinary tract infection
Common side effects
- Constipation
- Sleep disorder
- Nausea
- Headache
- Insomnia
- Diarrhoea
- Infustion site irritation
- Pyrexia
- Abdominal pain
- Infusion site erythema
- Infusion site extravasation
- Infustion site swelling
Drug interactions
- Aminoglycoside antibacterial drugs
- Potent diuretics (furosemide)
- Chloramphenicol
Key clinical trials
- Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB (PHASE4)
- PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection
- Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP (PHASE3)
- Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fortaz CI brief — competitive landscape report
- Fortaz updates RSS · CI watch RSS
- Pai Holdings Pharm portfolio CI